Dan Smith

Partner

Dan advises on high-stakes commercial disputes and investigations, particularly in the areas of investment and finance, complex commercial litigation, contentious restructurings and insolvencies, and bribery and corruption. Dan develops comprehensive dispute strategies early in line with clients’ business objectives, and achieving those objectives through litigation or alternative dispute resolution.

Dan’s life sciences experience includes:

  • Advising a major publicly-listed life sciences company in relation to a £200m+ dispute arising from supply of Covid-19 testing kits.
  • Advising a major life science company in relation to a c. £100m dispute relating to Covid-19 vaccinations.
  • Advising a publicly listed life sciences company in relation to a dispute with a public entity relating to Covid-19 tests.
  • Advising a security agent in relation to a contested rectification claim by an issuer in the healthcare sector in relation to the provision of security in relation to a series of £500+ million publicly-traded bonds.
  • Advising in relation to a wide variety of due diligence of life sciences and healthcare businesses in relation to bribery and corruption in the context of acquisitions, and investigations into actual or suspected wrongdoing.
  • Advising a medical devices company in relation to anti-corruption policies and procedures and NHS tender contracts.
  • Advising a pharma company in relation to third party diligence, contractual controls, and monitoring policies and procedures.
  • Advising a female healthcare company in relation to a demerger, including a transition and reconstruction plan for its compliance department.
  • Advising a cosmetics manufacturer in relation to modern slavery policies and procedures.
  • Advising a therapeutics company in relation to potential criminal activity and AML reporting obligations.